Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease

Ashish Verma; Ankit B Patel

doi:10.1016/j.tem.2021.02.002

Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease

Trends Endocrinol Metab. 2021 May;32(5):261-263. doi: 10.1016/j.tem.2021.02.002. Epub 2021 Feb 23.

Authors

Ashish Verma¹, Ankit B Patel²

Affiliations

¹ Renal Division, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: averma8@bwh.harvard.edu.
² Renal Division, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: Apatel38@bwh.harvard.edu.

PMID: 33637415
DOI: 10.1016/j.tem.2021.02.002

Abstract

Hemodynamic alterations, metabolic dysfunction, inflammation, and fibrosis are the main drivers of diabetic kidney disease (DKD) progression. Targeting inflammation and fibrosis as a driver, the FIDELIO-DKD (Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes) trial reported by Bakris et al. provides evidence of a new therapeutic class for treating DKD.

Keywords: FIDELIO-DKD; diabetic kidney disease; finerenone; non-steroidal mineralocorticoid receptor blocker.

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Diabetic Nephropathies* / drug therapy
Humans
Mineralocorticoid Receptor Antagonists* / therapeutic use
Naphthyridines*
Randomized Controlled Trials as Topic
Receptors, Mineralocorticoid

Substances

Mineralocorticoid Receptor Antagonists
Naphthyridines
Receptors, Mineralocorticoid
finerenone